

BC Cancer ST Program Updates for July 2026

AFFECTED APPLICATION(S)	PowerChart
AFFECTED AREA(S)	BC Cancer Sites / VCH Oncology Sites/ St. Paul's Hospital
NET NEW, OR UPDATE TO EXISTING BUILD	Update to Existing Build


What has Changed?

Any changes released that affect Oncology Regimens and PowerPlans/Cycles for the **BC Cancer Systemic Therapy (ST) Program** will be communicated monthly via Special Bulletin.

These notification changes are important for Nursing staff, Pharmacy, and Providers to be aware of for their patient's care.

For Providers:

- For PowerPlans that are versioned: If your patient has already started on a Regimen, when you order the next cycle PowerPlan, a pop-up window will appear to indicate a new version is required.
 - Click Yes to accept the new version.
 - Do not** use the Copy Forward functionality to ensure that the updates apply.



- IMPORTANT:** Any change from the standard treatment regimen (dose modification, addition of premed, etc.) in the previous cycle will need to be manually added to the cycle that is being ordered with the new version (see additional documentation regarding versioning).

Please see this month's changes below.

Protocols: HNNLAPRT

Cycles/PowerPlans: Associated PowerPlans and Regimens

Changes:

ONC HN HNNLAPRT

- **Update** regimen to include 1 instance of ONCP HN HNNLAPRT

ONC HN HNNLAPRT (Pending)

▼ Hide additional details

Regimen description: Treatment of Locally Advanced Nasopharyngeal Cancer with Concurrent Cisplatin and Radiation

+ Add

Document Response

View Responses

ONCP HN HNNLAPRT Pretreatment Plan

Start

*Est. Start Date: 01-Jul-2026

Skip

ONCP HN HNNLAPRT

*Est. Start Date: 01-Jul-2026

Extend

ONCP HN HNNLAPRT

Chemotherapy Phase:

- **Update** to include all cycles in this phase, noted as Day 1, 8, 15, 22, 29, 36, 43
- **Update** Pre-Chemo Metrics to 48 hours
- **Update** Pre-Hydration offset to -60 Minutes
- **Update** all medication order comments to include Days 1, 8, 15, 22, 29, 36, 43
- **Update** Cisplatin offset to 0 Minutes
- **Update** Cisplatin order comment to "May administer over 30 to 60 minutes. Days 1, 8, 15, 22, 29, 36, 43"

ONCP HN HNNLAPRT - Cycle 1, Chemotherapy (Day 1, 8, 15, 22, 29, 36, 43) (Future Pending) *Est. 01-Jul-2026 08:00 PDT - 43 Days									
	Component	Day 1	Day 8	Day 15	Day 22	Day 29	Day 36	Day 43	
		Future Pending *Est. 01-Jul-2026 08:00...	Future Pending *Est. 08-Jul-2026 08:00...	Future Pending *Est. 15-Jul-2026 08:00...	Future Pending *Est. 22-Jul-2026 08:00...	Future Pending *Est. 29-Jul-2026 08:00...	Future Pending *Est. 05-Aug-2026 08:00...	Future Pending *Est. 12-Aug-2026 08:00...	
		Actions	Actions	Actions	Actions	Actions	Actions	Actions	
	Link to Protocol: Treatment of Locally Advanced Nasopharyngeal Cancer with Concurrent Cisplatin and Radiation								
	Revised: 1 Jul 2026								
	DUAL MODALITY								
	Pre-Chemo Metrics								
	Neutrophils Greater Than or Equal to $0.8 \times 10^9/L$ within 48 hours								
	Platelet Count Greater Than or Equal to $100 \times 10^9/L$ within 48 hours								
	Creatinine Clearance Greater Than or Equal to 50 mL/min within 48 hours								
	Pre-Medications								
	Patient to take own supply of pre-medications. RN/Pharmacist to confirm								
☒	dexamethasone 8 mg, PO, once oncology, drug form: tab, Use Patient S... Between 30 and 60 minutes prior to treatment. Days 1, 8, 15, ...	-30 min Planned	-30 min Planned	-30 min Planned	-30 min Planned	-30 min Planned	-30 min Planned	-30 min Planned	-30 min Planned
☒	ondansetron 8 mg, PO, once oncology, drug form: tab, Use Patient Supply Do not give if patient given netupitant-palonosetron. Betwe...	-30 min Planned	-30 min Planned	-30 min Planned	-30 min Planned	-30 min Planned	-30 min Planned	-30 min Planned	-30 min Planned
☐	aprepitant 125 mg, PO, once oncology, drug form: cap, Use Patient Su... Between 30 and 60 minutes prior to treatment. Days 1, 8, 15, ...	-30 min	-30 min	-30 min	-30 min	-30 min	-30 min	-30 min	-30 min
	Reminder to deselect aprepitant and ondansetron if giving netupitant-palonosetron								
☐	netupitant-palonosetron (netupitant-palonosetron 300 ... 1 cap, PO, once oncology, drug form: cap, Use Patient Suppl... Between 30 and 60 minutes prior to treatment. Days 1, 8, 15, ...	-30 min	-30 min	-30 min	-30 min	-30 min	-30 min	-30 min	-30 min
☐	OLANzapine Select an order sentence	-30 min	-30 min	-30 min	-30 min	-30 min	-30 min	-30 min	-30 min
	Pre-Hydration								
☒	potassium chloride 20 mmol-magnesium sulfate 2 g /1... 20 mmol, IV, once oncology, administer over: 60 minute, dr... Pre-Cisplatin. Days 1, 8, 15, 22, 29, 36, 43	-60 min Planned	-60 min Planned	-60 min Planned	-60 min Planned	-60 min Planned	-60 min Planned	-60 min Planned	-60 min Planned
	Treatment Regimen								
☒	Zero Time	0 hr Planned	0 hr Planned	0 hr Planned	0 hr Planned	0 hr Planned	0 hr Planned	0 hr Planned	0 hr Planned
	Cisplatin is to be administered on a day on which radiation therapy is delivered. If radiation therapy is cancelled, do not give Cisplatin that day: postpone until radiation therapy resumes								
☒	Cisplatin (Cisplatin - oncology) 40 mg/m2, IV, once oncology, administer over: 30 minute, d... May administer over 30 to 60 minutes. Days 1, 8, 15, 22, 29, 3...	0 min Planned	0 min Planned	0 min Planned	0 min Planned	0 min Planned	0 min Planned	0 min Planned	0 min Planned
	Additional Orders								
	Any additional orders will be displayed below. Please review and adjust scheduled administration time as nee...								
Schedulable Orders									
☒	Infusion Chemotherapy Visit Within 2 Weeks, DUAL MODALITY. Chair time 180 minutes; ... Day 1	Planned							
☒	Infusion Chemotherapy Visit Within 2 Weeks, DUAL MODALITY. Chair time 180 minutes; ... Day 8		Planned						
☒	Infusion Chemotherapy Visit Within 2 Weeks, DUAL MODALITY. Chair time 180 minutes; ... Day 15			Planned					
☒	Infusion Chemotherapy Visit Within 2 Weeks, DUAL MODALITY. Chair time 180 minutes; ... Day 22				Planned				
☒	Infusion Chemotherapy Visit Within 2 Weeks, DUAL MODALITY. Chair time 180 minutes; ... Day 29					Planned			
☒	Infusion Chemotherapy Visit Within 2 Weeks, DUAL MODALITY. Chair time 180 minutes; ... Day 36						Planned		
☒	Infusion Chemotherapy Visit Within 2 Weeks, DUAL MODALITY. Chair time 180 minutes; ... Day 43							Planned	

Scheduling Phase:

- **Add** Infusion Chemotherapy Visit orders (preselected) for Days 8, 15, 22, 29, 36, 43
- **Update** Follow Up - Clinic - Oncology On Treatment order to "Follow Up: As per Special Instructions, Prior to Day 8 treatment, Physician Specialty: Medical Oncology, Tumor Group: Head and Neck", with +7 day offset
- **Add** Follow Up - Clinic - Oncology On Treatment orders (preselected) for prior to Day 15, 22, 29, 36, 43, with offsets of +14, +21, +28, +35 and +42 day

ONCP HN HNNLPRT - Cycle 1, Scheduling (Initiated Pending)		
☒	☒ Infusion Chemotherapy Visit	Within 2 Weeks, DUAL MODALITY. Chair time 180 minutes; Nurse time 60 minutes, Chair Time: 165 minutes, Nurse Time: 45 minutes, ONCP HN HNNLPRT Day 1
☒	☒ Infusion Chemotherapy Visit	Within 2 Weeks, DUAL MODALITY. Chair time 180 minutes; Nurse time 60 minutes, Chair Time: 165 minutes, Nurse Time: 45 minutes, ONCP HN HNNLPRT Day 8
☒	☒ Infusion Chemotherapy Visit	Within 2 Weeks, DUAL MODALITY. Chair time 180 minutes; Nurse time 60 minutes, Chair Time: 165 minutes, Nurse Time: 45 minutes, ONCP HN HNNLPRT Day 15
☒	☒ Infusion Chemotherapy Visit	Within 2 Weeks, DUAL MODALITY. Chair time 180 minutes; Nurse time 60 minutes, Chair Time: 165 minutes, Nurse Time: 45 minutes, ONCP HN HNNLPRT Day 22
☒	☒ Infusion Chemotherapy Visit	Within 2 Weeks, DUAL MODALITY. Chair time 180 minutes; Nurse time 60 minutes, Chair Time: 165 minutes, Nurse Time: 45 minutes, ONCP HN HNNLPRT Day 29
☒	☒ Infusion Chemotherapy Visit	Within 2 Weeks, DUAL MODALITY. Chair time 180 minutes; Nurse time 60 minutes, Chair Time: 165 minutes, Nurse Time: 45 minutes, ONCP HN HNNLPRT Day 36
☒	☒ Infusion Chemotherapy Visit	Within 2 Weeks, DUAL MODALITY. Chair time 180 minutes; Nurse time 60 minutes, Chair Time: 165 minutes, Nurse Time: 45 minutes, ONCP HN HNNLPRT Day 43
☒	☒ + 7 day Follow Up - Clinic - Oncology On Treatment	Follow Up: As per Special Instructions, Prior to Day 8 treatment, Physician Specialty: Medical Oncology, Tumor Group: Head and Neck
☒	☒ + 14 day Follow Up - Clinic - Oncology On Treatment	Follow Up: As per Special Instructions, Prior to Day 15 treatment, Physician Specialty: Medical Oncology, Tumor Group: Head and Neck
☒	☒ + 21 day Follow Up - Clinic - Oncology On Treatment	Follow Up: As per Special Instructions, Prior to Day 22 treatment, Physician Specialty: Medical Oncology, Tumor Group: Head and Neck
☒	☒ + 28 day Follow Up - Clinic - Oncology On Treatment	Follow Up: As per Special Instructions, Prior to Day 29 treatment, Physician Specialty: Medical Oncology, Tumor Group: Head and Neck
☒	☒ + 35 day Follow Up - Clinic - Oncology On Treatment	Follow Up: As per Special Instructions, Prior to Day 36 treatment, Physician Specialty: Medical Oncology, Tumor Group: Head and Neck
☒	☒ + 42 day Follow Up - Clinic - Oncology On Treatment	Follow Up: As per Special Instructions, Prior to Day 43 treatment, Physician Specialty: Medical Oncology, Tumor Group: Head and Neck
Go to Chemo Calendar to send next cycle to scheduling wait list		

Versioning: Yes

Jira: CST-372202

Protocols: ULUAVPPAF and ULUAVPPAMI

Cycles/PowerPlans:

ONCP LU ULUAVPPAF Baseline Weight 80 kg or more Cycles 5+
ONCP LU ULUAVPPAF Baseline Weight less than 80 kg Cycles 5+
ONCP LU ULUAVPPAMI Baseline Weight 80 kg or more Cycles 5+
ONCP LU ULUAVPPAMI Baseline Weight less than 80 kg Cycles 5+

Changes:

- Added CDS note: "If dexamethasone IV is being given as amivantamab premedication, deselect dexamethasone PO"
- Added dexamethasone PO 8mg and 12mg options
order comment: Between 30 and 60 minutes prior to treatment. Day 1
- Added linked components for dexamethasone PO and IV so only one can be selected

Versioning: Yes

Jira: CST-371316

Protocols: GIAJNIV, GIGAVFFOXN, GUAVIPNI, GUAVNIV, GUAVNIV4, GUAVNIVC, GUAVNIVC4, UGUAJNIV, UGUAJNIV4, HNAVNI, HNAVNI4, LUAVNIV, LUAVNIV4, SMAJNIV, SMAJNIV4, SMAVNIV, SMAVNIV4, SMAVALIPNI, SMAVIPNI, LUNANIVPP, LUNANIVPC, GIGAVCOXN

Cycles/PowerPlans: All Associated PowerPlans

Changes:

PowerPlans:

- ONCP GI GIGAVFFOXN
- ONCP GU GUAVNIV
- ONCP GU UGUAJNIV
- ONCP GU GUAVNIVC Cycles 1 to 52
- ONCP GU GUAVIPNI Every 2 Week Maintenance
- ONCP HN HNAVNI
- ONCP LU LUAVNIV
- ONCP SM SMAJNIV
- ONCP SM SMAVNIV
- ONCP SM SMAVALIPNI Every 2 Week Maintenance
- ONCP SM SMAVIPNI Every 2 week Maintenance

Chemotherapy phase within Treatment Regimen:

- ADDED an unselected order: nivolumab subcut-oncology: 600 mg, subcutaneous, once oncology, administer over: 3 minute, drug form: syringe-inj, first dose: Routine.
- Order comment: Subcutaneous Injection: Inject into abdomen or thigh over 3 to 5 minutes
- ADDED a teal banner below subcutaneous nivolumab "During treatment with subcutaneous nivolumab, administer other subcutaneous drugs at alternate injection sites whenever possible"

- Both nivolumab orders are unselected and linked so provider can only choose one order.

☐	 nivolumab (nivolumab subcut - oncology) 600 mg, subcutaneous, once oncology, administer over: 3 minute, drug form: syringe-inj, first dose: Routine Subcutaneous Injection: Inject into abdomen or thigh over 3 to 5 minutes. Day 1	0 min
	 During treatment with subcutaneous nivolumab, administer other subcutaneous drugs at alternate injection sites whenever possible	
☐	 nivolumab (nivolumab - oncology (CAPPED 240 mg)) 3 mg/kg, IV, once oncology, administer over: 30 minute, drug form: bag Max Dose: 240 mg. Use a 0.2 micron in-line filter. Day 1	0 min

PowerPlans:

- ONCP GI GIAJNIV
- ONCP GU GUAVIPNI Every 4 Week Maintenance
- ONCP GU GUAVNIV4
- ONCP GU GUAVNIVC4 Cycles 1 to 26
- ONCP GU UGUAJNIV4
- ONCP HN HNAVIV4
- ONCP LU LUAVNIV4
- ONCP SM SMAJNIV4
- ONCP SM SMAVNIV4
- ONCP SM SMAVALIPNI Every 4 Week Maintenance
- ONCP SM SMAVIPNI Every 4 Week Maintenance

Chemotherapy phase within Treatment Regimen:

- ADDED an unselected order: nivolumab subcut-oncology: 1200 mg, subcutaneous, once oncology, administer over: 3 minute, drug form: syringe-inj, first dose: Routine.
- Order comment: Subcutaneous Injection: Inject into abdomen or thigh over 3 to 5 minutes
- ADDED a teal banner below subcutaneous nivolumab "During treatment with subcutaneous nivolumab, administer other subcutaneous drugs at alternate injection sites whenever possible"
- Both nivolumab orders are unselected and linked so provider can only choose one order.

☐	 nivolumab (nivolumab subcut - oncology) 1,200 mg, subcutaneous, once oncology, administer over: 3 minute, drug form: syringe-inj, first dose: Routine Subcutaneous Injection: Inject into abdomen or thigh over 3 to 5 minutes. Day 1	0 min
	 During treatment with subcutaneous nivolumab, administer other subcutaneous drugs at alternate injection sites whenever possible	
☐	 nivolumab (nivolumab - oncology (CAPPED 480 mg)) 6 mg/kg, IV, once oncology, administer over: 30 minute, drug form: bag Max Dose: 480 mg. Use a 0.2 micron in-line filter. Day 1	0 min

PowerPlans:

- ONCP LU LUNANIVPP Carboplatin option
- ONCP LU LUNANIVPP Cisplatin option
- ONCP LU LUNANIVPC
- ONCP GI GIGAVCOXN

Chemotherapy phase within Treatment Regimen:

- ADDED an unselected order: nivolumab subcut-oncology: 900 mg, subcutaneous, once oncology, administer over: 3 minute, drug form: syringe-inj, first dose: Routine.
- Order comment: Subcutaneous Injection: Inject into abdomen or thigh over 3 to 5 minutes
- ADDED a teal banner below subcutaneous nivolumab “During treatment with subcutaneous nivolumab, administer other subcutaneous drugs at alternate injection sites whenever possible”
- Both nivolumab orders are unselected and linked so provider can only choose one order.

☐	 nivolumab (nivolumab subcut - oncology) 900 mg, subcutaneous, once oncology, administer over: 3 minute, drug form: syringe-inj, first dose: Routine Subcutaneous Injection: Inject into abdomen or thigh over 3 to 5 minutes. Day 1	0 min
	 During treatment with subcutaneous nivolumab, administer other subcutaneous drugs at alternate injection sites whenever possible	
	 Nivolumab line to be primed with sodium chloride 0.9%; Oxaliplatin line to be primed with dextrose 5%	
☐	 nivolumab (nivolumab - oncology (CAPPED 360 mg)) 4.5 mg/kg, IV, once oncology, administer over: 30 minute, drug form: bag Max Dose: 360 mg. Use a 0.2 micron in-line filter. Day 1	0 min

Versioning: Yes

Jira: CST-370433

Protocols: LYCLLIV

Cycles/PowerPlans:

ONCP LY LYCLLIV Low/Moderate TLS Risk Ramp-Up Cycle 4 Weeks 1 to 5 (PO)
ONCP LY LYCLLIV Post Ramp-Up Cycles 5 to 15 (PO)
ONCP LY LYCLLIV High TLS Risk Ramp-Up Cycle 4 Week 1 (Inpatient)
ONCP LY LYCLLIV High TLS Risk Ramp-Up Cycle 4 Week 2 (Inpatient)
ONCP LY LYCLLIV High TLS Risk Ramp-Up Cycle 4 Weeks 3 to 5 (PO)

Changes:

Updated Pre-Chemo Metrics

- **Updated** Yellow CDS Note: Changed “May proceed with **ibrutinib** as written if within 96 hours:” to “May proceed with **doses** as written if within 96 hours
- **Deleted** Yellow CDS Note: May proceed with venetoclax as written if within 96 hours of venetoclax initiation:
- **Deleted** White CDS Notes related to venetoclax:
 - Neutrophils Greater Than or Equal to $1.0 \times 10^9/L$
 - Platelet Count Greater Than or Equal to $50 \times 10^9/L$
 - Total Bilirubin Less Than or Equal to 3 x ULN

Component	Status	Dose ...	Details
ONCP LY LYCLLIV Post Ramp-Up Cycles 5 to 15 (PO) - Cycle 5, Prescriptions (Future Pending)			
Link to Protocol: Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Using iBRTinib and Venetoclax			
Revised: 2 July 2026			
Pre-Chemo Metrics			
May proceed with doses as written if within 96 hours:			
Neutrophils Greater Than or Equal to $1.0 \times 10^9/L$			
Platelet Count Greater Than or Equal to $50 \times 10^9/L$			

Versioning: Yes

Jira: CST-372177

Protocols: LUAJALE and LUVALE

Cycles/PowerPlans: All Associated PowerPlans

Changes:

For ONCP LU LUVALE Pretreatment Plan and ONCP LU LUAJALE Pretreatment Plan:

- Added Triglyceride order to Baseline Labs phase

Orders for Signature ☒ ONCP LK ULKAMLAZIV (7 Days On) (Started) ☐ ONCP LK ULKAMLAZIV Pretreatment Plan Baseline Labs (Day 1) (Future) Diagnostics (Future) ☐ ONCP LK ULKAMLAZIV (7 Days On) Cycle 1 - Cycle Chemotherapy (Day 1 to 7) (Future) Prescriptions (Future) Prescriptions (Inpatient Use Only) (Planned) Labs (Day 3, 5, 8, 15, 22, 29) (Future) Diagnostics (Future) Scheduling (Initiated) ☐ Plans ☐ Document In Plan ☐ Oncology ☐ ONCP LU LUAJALE Pretreatment Plan ☒ Baseline Labs (Day 1) (Future Pending) ☒ Diagnostics (Future Pending) ☐ ONCP GI GIPGEM - Cycle 1		ONCP LU LUAJALE Pretreatment Plan, Baseline Labs (Day 1) (Future Pending) *Est. 23-Jun-2026 08:00 PDT - 1 Days	
	Component	Day 1	
		Future Pending	*Est. 23-Jun-2026...
		Actions	
☒	☒ Alkaline Phosphatase Blood, once, Order for future visit	Planned	
☒	☒ Alanine Aminotransferase Blood, once, Order for future visit	Planned	
☒	☒ Bilirubin Total Blood, once, Order for future visit	Planned	
☒	☒ Lactate Dehydrogenase Blood, once, Order for future visit	Planned	
☒	☒ Creatine Kinase Blood, once, Order for future visit	Planned	
☒	☒ Triglyceride Blood, once, Order for future visit	Planned	

For **ONCP LU LUAJALE (PO) Cycle 1** and **ONCP LU LUAJALE (PO) Cycles 2 to 3** and **ONCP LU LUVALE (PO) Cycle 1** and **ONCP LU LUVALE (PO) Cycles 2 to 3**:

- Added Triglyceride order under Labs phase for Days 15 and 29

Orders for Signature ☒ ONCP LK ULKAMLAZIV (7 Days On) (Started) ☐ ONCP LK ULKAMLAZIV Pretreatment Plan Baseline Labs (Day 1) (Future) Diagnostics (Future) ☐ ONCP LK ULKAMLAZIV (7 Days On) Cycle 1 - Cycle Chemotherapy (Day 1 to 7) (Future) Prescriptions (Future) Prescriptions (Inpatient Use Only) (Planned) Labs (Day 3, 5, 8, 15, 22, 29) (Future) Diagnostics (Future) Scheduling (Initiated) ☐ Plans ☐ Document In Plan ☐ Oncology ☐ ONCP LU LUAJALE (PO) Cycle 1 - Cycle 1 ☒ Prescriptions (Future Pending) ☒ Scheduling (Initiated Pending) ☒ Labs (Day 15, 29) (Future Pending)		ONCP LU LUAJALE (PO) Cycle 1 - Cycle 1, Labs (Day 15, 29) (Future Pending) *Est. 05-Jul-2026 15:38 PDT - 29 Days	
	Component	Day 15	Day 29
		Future Pending	Future Pending
		*Est. 05-Jul-2026 ...	*Est. 19-Jul-2026 ...
		Actions	Actions
☒	☒ Alkaline Phosphatase Blood, once, Order for future visit	Planned	Planned
☒	☒ Alanine Aminotransferase Blood, once, Order for future visit	Planned	Planned
☒	☒ Bilirubin Total Blood, once, Order for future visit	Planned	Planned
☒	☒ Lactate Dehydrogenase Blood, once, Order for future visit	Planned	Planned
☒	☒ Creatine Kinase Blood, once, Order for future visit	Planned	Planned
☒	☒ Triglyceride Blood, once, Order for future visit	Planned	Planned
☐	☐ If clinically indicated:		
☐	☐ Calcium Level		

For **ONCP LU LUVALE (PO) Cycles 4+** and **ONCP LU LUAJALE (PO) Cycles 4+**:

- Added Triglyceride order under Next Cycle Labs phase

View Orders for Signature ☒ ONCP LK ULKAMLAZIV (7 Days On) (Started) ☐ ONCP LK ULKAMLAZIV Pretreatment Plan Baseline Labs (Day 1) (Future) Diagnostics (Future) ☐ ONCP LK ULKAMLAZIV (7 Days On) Cycle 1 - Cycle Chemotherapy (Day 1 to 7) (Future) Prescriptions (Future) Prescriptions (Inpatient Use Only) (Planned) Labs (Day 3, 5, 8, 15, 22, 29) (Future) Diagnostics (Future) Scheduling (Initiated) ☐ Plans ☐ Document In Plan ☐ Oncology ☐ ONCP LU LUVALE (PO) Cycles 4+ - Cycle 2 ☒ Prescriptions (Future Pending) ☒ Scheduling (Initiated Pending) ☒ Next Cycle Labs (Day 1) (Future Pending)		ONCP LU LUVALE (PO) Cycles 4+ - Cycle 2, Next Cycle Labs (Day 1) (Future Pending) *Est. 20-Jul-2026 15:39 PDT - 28 Days	
	Component	Day 1	
		Future Pending	*Est. 20-Jul-2026 ...
		Actions	
☒	☒ CBC and Differential Blood, once, Order for future visit	Planned	
☒	☒ Alkaline Phosphatase Blood, once, Order for future visit	Planned	
☒	☒ Alanine Aminotransferase Blood, once, Order for future visit	Planned	
☒	☒ Bilirubin Total Blood, once, Order for future visit	Planned	
☒	☒ Lactate Dehydrogenase Blood, once, Order for future visit	Planned	
☒	☒ Triglyceride Blood, once, Order for future visit	Planned	
☐	☐ If clinically indicated:		
☐	☐ Creatine Kinase		

Versioning: Yes

Jira: CST-371464

Protocols: Change MYDBLDF Protocol Code to MYDBLDFTE

Cycles/PowerPlans:

ONCP MY MYDBLDFTE Female of Childbearing Potential (FCBP) Pretreatment Plan
 ONCP MY MYDBLDFTE Female of Childbearing Potential (FCBP) Consolidation Pretreatment Plan
 ONCP MY MYDBLDFTE Female of Childbearing Potential (FCBP) Induction Cycle 1
 ONCP MY MYDBLDFTE Female of Childbearing Potential (FCBP) Induction Cycle 2
 ONCP MY MYDBLDFTE Female of Childbearing Potential (FCBP) Induction Cycles 3 and 4
 ONCP MY MYDBLDFTE Female of Childbearing Potential (FCBP) Consolidation Cycle
 ONCP MY MYDBLDFTE Female of Childbearing Potential (FCBP) Consolidation Cycle 6
 ONCP MY MYDBLDFTE Female of Childbearing Potential (FCBP) Daratumumab Restart Cycle 1
 ONCP MY MYDBLDFTE Female of Childbearing Potential (FCBP) Daratumumab Restart Cycle 2
 ONCP MY MYDBLDFTE Female of Childbearing Potential Daratumumab Restart Cycles 3 to 6
 ONCP MY MYDBLDFTE Female of Childbearing Potential Daratumumab Restart Cycles 7+
 ONCP MY MYDBLDFTE Female of Childbearing Potential (FCBP) Maintenance Cycles 7+
 ONCP MY MYDBLDFTE Non Childbearing Potential (NCBP) Pretreatment Plan
 ONCP MY MYDBLDFTE Non Childbearing Potential (NCBP) Consolidation Pretreatment Plan
 ONCP MY MYDBLDFTE Non Childbearing Potential (NCBP) Induction Cycle 1
 ONCP MY MYDBLDFTE Non Childbearing Potential (NCBP) Induction Cycle 2
 ONCP MY MYDBLDFTE Non Childbearing Potential (NCBP) Induction Cycles 3 and 4
 ONCP MY MYDBLDFTE Non Childbearing Potential (NCBP) Consolidation Cycles 5 and 6
 ONCP MY MYDBLDFTE Non Childbearing Potential (NCBP) Daratumumab Restart Cycle 1
 ONCP MY MYDBLDFTE Non Childbearing Potential (NCBP) Daratumumab Restart Cycle 2
 ONCP MY MYDBLDFTE Non Childbearing Potential (NCBP) Daratumumab Restart Cycles 3 to 6
 ONCP MY MYDBLDFTE Non Childbearing Potential (NCBP) Daratumumab Restart Cycles 7+
 ONCP MY MYDBLDFTE Non Childbearing Potential (NCBP) Maintenance Cycles 7+

Regimens

ONC MY MYDBLDFTE Female of Childbearing Potential (FCBP) Consolidation and Maintenance
 ONC MY MYDBLDFTE Female of Childbearing Potential (FCBP) Induction Phase
 ONC MY MYDBLDFTE Female of Childbearing Potential (FCBP) Maintenance Daratumumab Restart
 ONC MY MYDBLDFTE Non Childbearing Potential (NCBP) Consolidation and Maintenance

ONC MY MYDBLDFTE Non Childbearing Potential (NCBP) Induction Phase

ONC MY MYDBLDFTE Non Childbearing Potential (NCBP) Maintenance Daratumumab Restart

Changes:

Update protocol code in all applicable areas from MYDBLDF to MYDBLDFTE

Updated protocol code in all PowerPlan and Regimen names from MYDBLF to MYDBLDFTE

ONC MY MYDBLDFTE Female of Childbearing Potential (FCBP) Consolidation and Maintenance

[ONC MY MYDBLDFTE Female of Childbearing Potential \(FCBP\) Induction Phase](#)

ONC MY MYDBLDFTE Female of Childbearing Potential (FCBP) Maintenance Daratumumab Restart

ONC MY MYDBLDFTE Non Childbearing Potential (NCBP) Consolidation and Maintenance

ONC MY MYDBLDFTE Non Childbearing Potential (NCBP) Induction Phase

ONC MY MYDBLDFTE Non Childbearing Potential (NCBP) Maintenance Daratumumab Restart

ONCP MY MYDBLDFTE Non Childbearing Potential (NCBP) Maintenance Cycles 7+

ONCP MY MYDBLDFTE Female of Childbearing Potential (FCBP) Consolidation Cycle 5

ONCP MY MYDBLDFTE Female of Childbearing Potential (FCBP) Consolidation Cycle 6

ONCP MY MYDBLDFTE Female of Childbearing Potential (FCBP) Consolidation Pretreatment Plan

ONCP MY MYDBLDFTE Female of Childbearing Potential (FCBP) Daratumumab Restart Cycle 1

ONCP MY MYDBLDFTE Female of Childbearing Potential (FCBP) Daratumumab Restart Cycle 2

ONCP MY MYDBLDFTE Female of Childbearing Potential (FCBP) Induction Cycle 1

ONCP MY MYDBLDFTE Female of Childbearing Potential (FCBP) Induction Cycle 2

ONCP MY MYDBLDFTE Female of Childbearing Potential (FCBP) Induction Cycles 3 and 4

ONCP MY MYDBLDFTE Female of Childbearing Potential (FCBP) Maintenance Cycles 7+

ONCP MY MYDBLDFTE Female of Childbearing Potential (FCBP) Pretreatment Plan

ONCP MY MYDBLDFTE Non Childbearing Potential (NCBP) Consolidation Cycles 5 and 6

ONCP MY MYDBLDFTE Non Childbearing Potential (NCBP) Consolidation Pretreatment Plan

ONCP MY MYDBLDFTE Non Childbearing Potential (NCBP) Daratumumab Restart Cycle 1

ONCP MY MYDBLDFTE Non Childbearing Potential (NCBP) Daratumumab Restart Cycle 2

ONCP MY MYDBLDFTE Non Childbearing Potential (NCBP) Daratumumab Restart Cycles 3 to 6

ONCP MY MYDBLDFTE Non Childbearing Potential (NCBP) Daratumumab Restart Cycles 7+

ONCP MY MYDBLDFTE Non Childbearing Potential (NCBP) Induction Cycle 1

ONCP MY MYDBLDFTE Non Childbearing Potential (NCBP) Induction Cycle 2

ONCP MY MYDBLDFTE Non Childbearing Potential (NCBP) Induction Cycles 3 and 4

ONCP MY MYDBLDFTE Non Childbearing Potential (NCBP) Pretreatment Plan

Updated protocol code in all evidence Links from MYDBLF to MYDBLDFTE (not applicable for Pretreatment Plans)

Updated *Infusion Chemotherapy Visit* orders with updated protocol code from MYDBLF to MYDBLDFTE (not applicable for Pretreatment Plans)

4 ONCP MY MYDBLDFTE Female of Childbearing Potential (FCBP) Induction Cycle 1 - Cycle 1 Scheduling Initiated Pending) 23-Jun-2026 08:00 PDT		
☒ ☒ Infusion Chemotherapy Visit	Within 2 Weeks, Chair Time: 135 minutes, Nurse Time: 90 minutes, ONCP MY MYDBLDFTE Female of Childbearing Potential (FCBP) Induction Cycle 1 Day 1	
☒ ☒ Infusion Chemotherapy Visit	Within 2 Weeks, Chair Time: 45 minutes, Nurse Time: 45 minutes, ONCP MY MYDBLDFTE Female of Childbearing Potential (FCBP) Induction Cycle 1 Day 8	
☒ ☒ Infusion Chemotherapy Visit	Within 2 Weeks, Chair Time: 45 minutes, Nurse Time: 45 minutes, ONCP MY MYDBLDFTE Female of Childbearing Potential (FCBP) Induction Cycle 1 Day 15	
☒ ☒ Infusion Chemotherapy Visit	Within 2 Weeks, Chair Time: 45 minutes, Nurse Time: 45 minutes, ONCP MY MYDBLDFTE Female of Childbearing Potential (FCBP) Induction Cycle 1 Day 22	
☒ ☒ Follow Up - Clinic - Oncology On Treatment	Physician Specialty: Medical Oncology, Tumor Group: Lymphoma and Myeloma	
Go to Chemo Calendar to send next cycle to scheduling wait list		

Versioning: Yes

Jira: CST-370037

Protocols: BRAJLHRHAI, BRAJLHRHT, BRAVLHRHAI, UBRAJABET, UBRAJABEI, BRAVLHRHT, BRAVRBFLV, BRAVPBFLV, BRAVRIBAI, BRAVPALAI, UBRAVCAFLV,

Cycles/PowerPlans: All associated treatment plans

Changes:

ONCP BR BRAJLHRHT (PO) (6 months) Cycle 1 / ONCP BR BRAJLHRHT (PO) (6 months) Cycles 2+

- Added New Labs Phase
- Added New If Clinically Indicated: banner
- Added unselected LH (Luteinizing Hormone)
- Added unselected FSH (Follicle Stimulating Hormone)
- Added unselected Estradiol Level

ONCP BR BRAJLHRHT (PO) (6 months) Cycle 1 - Cycle 1, Labs (Day 1) (Planned)				
				Day 1
				Planned Pending
				*Est. 26-Jun-2026...
				Actions ▾
			If clinically indicated:	
☐	☒	Luteinizing Hormone	Blood, once, Order for future visit	
☐	☒	Follicle Stimulating Hormone	Blood, once, Order for future visit	
☐	☒	Estradiol Level	Blood, once, Order for future visit	

All other plans

- Add unselected LH (Luteinizing Hormone)
- Add unselected FSH (Follicle Stimulating Hormone)
- Add unselected Estradiol Level

ONCP BR BRAJLHRHAI (PO) (6 months) Cycle 1 - Cycle 1, Labs (Day 1) (Future)				
				Day 1
				Future Pending
				*Est. 26-Jun-2026...
				Actions ▾
			If clinically indicated:	
☐	☒	Luteinizing Hormone	Blood, once, Order for future visit	
☐	☒	Follicle Stimulating Hormone	Blood, once, Order for future visit	
☐	☒	Estradiol Level	Blood, once, Order for future visit	
☐	☒	Cholesterol Level	Blood, once, Order for future visit	
☐	☒	Triglyceride	Blood, once, Order for future visit	

Versioning: Yes

Jira: CST-369411

Protocols: UMYTEC

Cycles/PowerPlans: ONCP MY UMYTEC teclistamab Cycles 2+

Changes:

- Removed the following Clinical Decision Support note: “May proceed with treatment if no signs or symptoms or CRS or ICANS” within Pre-Chemo Metrics

ONCP MY UMYTEC teclistamab Cycles 2+ - Cycle 2, Chemotherapy (Day 1, 8, 15, 22) (Future Pending) *Es

	Component
	Link to Protocol: Treatment of Relapsed and Refractory Multiple Myeloma using Teclistamab
	Revised: 2 Jul 2026
	Pre-Chemo Metrics
	Neutrophils Greater Than or Equal to $0.5 \times 10^9/L$ within 48 hours
	Platelet Count Greater Than or Equal to $25 \times 10^9/L$ (without bleeding) within 48 hours

Versioning: Yes

Jira: CST-373346

Net New Protocols

- ONC LY LYMCIV High TLS Risk
- ONC LY LYMCIV Low/Moderate TLS Risk
- ONCP LY LYMCIV Pretreatment Plan
- ONCP LY LYMCIV High TLS Risk Ramp-Up Cycle 1 Week 1 (Inpatient)
- ONCP LY LYMCIV High TLS Risk Ramp-Up Cycle 1 Week 2 (Inpatient)
- ONCP LY LYMCIV High TLS Risk Ramp-Up Cycle 1 Weeks 3 to 5 (PO)
- ONCP LY LYMCIV High TLS Risk Ramp-Up Prescriptions Cycle 1 Weeks 1 to 5
- ONCP LY LYMCIV Low/Moderate TLS Risk Ramp-Up Cycle 1 Weeks 1 to 5 (PO)
- ONCP LY LYMCIV Post Ramp-Up Cycles 2 to 23 (PO)
- ONCP LY LYMCIV Post Ramp-Up Cycles 24+ (PO)
-
- ONC MY MYDBLFTI Female of Childbearing Potential (FCBP)

- ONC MY MYDBLDFTI Non Childbearing Potential (NCBP)
- ONCP MY MYDBLDFTI Female of Childbearing Potential (FCBP) Pretreatment Plan
- ONCP MY MYDBLDFTI Female of Childbearing Potential (FCBP) Cycle 1
- ONCP MY MYDBLDFTI Female of Childbearing Potential (FCBP) Cycle 2
- ONCP MY MYDBLDFTI Female of Childbearing Potential (FCBP) Cycles 3 and 4
- ONCP MY MYDBLDFTI Female of Childbearing Potential (FCBP) Cycles 5 to 8
- ONCP MY MYDBLDFTI Female of Childbearing Potential (FCBP) Cycles 9+
- ONCP MY MYDBLDFTI Non Childbearing Potential (NCBP) Pretreatment Plan
- ONCP MY MYDBLDFTI Non Childbearing Potential (NCBP) Cycles 1 and 2
- ONCP MY MYDBLDFTI Non Childbearing Potential (NCBP) Cycles 3 and 4
- ONCP MY MYDBLDFTI Non Childbearing Potential (NCBP) Cycles 5 to 8
- ONCP MY MYDBLDFTI Non Childbearing Potential (NCBP) Cycles 9+

Jira: CST-371463, CST-370036

Jira Ticket #	CST-373346, CST-372202, CST-372177, CST-371464, CST-371316, CST-370433, CST-370037, CST-369411
How-to questions?	http://cstcernerhelp.healthcarebc.ca
Need further support?	CST Cerner Phone Support: 1-844-214-7444